SHR-A1201 is an antibody-drug conjugate (ADC) targeting HER2. This compound is composed of a humanized anti-HER2 antibody, the linker SMCC, and the cytotoxic payload Mertansine, which is a microtubule inhibitor. SHR-A1201 is utilized in research for HER2-positive breast cancer.
Molecular Weight:
1018.51
Formula:
C50H63ClF3N5O12
Target:
EGFR|||Antibody-Drug Conjugates (ADCs)
T9901A-238
* VAT and and shipping costs not included. Errors and price changes excepted